C
Chris Parker
Researcher at Institute of Cancer Research
Publications - 479
Citations - 35757
Chris Parker is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 79, co-authored 422 publications receiving 30260 citations. Previous affiliations of Chris Parker include The Royal Marsden NHS Foundation Trust & University of Toronto.
Papers
More filters
Journal ArticleDOI
Apparent diffusion coefficient as a predictive biomarker of prostate cancer progression: value of fast and slow diffusion components.
TL;DR: Both fast and slow diffusion components were significantly lower in tumors that were subsequently upgraded on histology in patients managed by active surveillance, and both tumor volume and the true diffusion ADC(slow) were significant but independent predictors of histologic progression.
Journal ArticleDOI
Current approaches to incorporation of radium-223 in clinical practice.
TL;DR: Radium-223 prolongs overall survival and delays time to the first symptomatic skeletal events in men with mCRPC, and is indicated for the treatment of patients with CRPC, symptomatic bone metastases, and no known visceral metastases.
Journal ArticleDOI
Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer.
R. Venkitaraman,Gary Cook,David P. Dearnaley,Chris Parker,Khoo,Rosalind A. Eeles,Robert Huddart,Alan Horwich,S.A. Sohaib +8 more
TL;DR: Whole‐body MRI and radionuclide bone scintigraphy have similar specificity and sensitivity and may be used as complementary investigations to detect skeletal metastases from prostate cancer.
Journal ArticleDOI
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
Nicholas D. James,Nicholas D. James,Sarah Pirrie,Ann Pope,Darren Barton,Lazaros Andronis,Ilias Goranitis,Stuart Collins,Duncan McLaren,Joe M. O'Sullivan,Chris Parker,Emilio Porfiri,John Staffurth,Andrew Stanley,James D. Wylie,Sharon Beesley,Alison Birtle,Janet E. Brown,Prabir Chakraborti,Martin J. Russell,Lucinda Billingham +20 more
TL;DR: A two-by-two factorial randomised controlled trial of zoledronic acid and strontium-89, each combined with docetaxel, to determine the clinical effectiveness and cost-effectiveness of each agent.
Journal ArticleDOI
Active surveillance with selective radical treatment for localized prostate cancer.
Nicholas van As,Chris Parker +1 more
TL;DR: The rationale for active surveillance, the early results, and uncertainty regarding the interpretation of PSA kinetics, repeat biopsy results and prostate imaging are discussed.